{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Ojons4IDA","founded_year":1891,"lastupdate":"2023-01-24T00:00:00.000Z","update_date":"2023-01-24T00:00:00.000Z","lastModified":"Oct 14, 2024","confidence_score":66,"active":1,"confidence_score_reason":"product stage, sector, founding month, business model, video or image, funding rounds, markets, not claimed","urlname":"takeda","minimal_profile":null,"status":"Public","fullstatus":"Public on TYO on Dec, 2013;Public on NYSE on Dec, 2018;","acquired":0,"description_edited":0,"tag_line_edited":0,"phone":"","registrar":null,"biverification":"Vered Waxman","recentupdates":[{"email":"vichian9703@gmail.com","source":"Automatic","datetime":"2023-04-04 08:20:02.000000","last_name":"suksoir","first_name":"vichian"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:49:30.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-24 19:49:03.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-11 19:48:21.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-15 16:49:05.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-14 10:08:08.000000","last_name":"Perlov","first_name":"Maor"},{"email":"matane@sncentral.org","source":"Automatic","datetime":"2023-03-21 17:22:29.000000","last_name":"Eblagon","first_name":"Matan"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-22 13:09:35.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-11 19:48:21.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-01-24 19:52:44.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-24 19:42:52.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:49:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:49:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:01:30.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-14 10:08:08.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:49:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-22 06:36:19.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-24 19:42:52.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:55:38.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:49:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:49:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:49:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:49:30.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:21:32.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2025-02-06 12:26:57.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-24 19:49:03.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:48:49.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-31 12:40:52.000000","last_name":"Perlov","first_name":"Maor"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 18:20:13.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 18:20:13.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 18:20:13.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 18:20:13.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 18:20:13.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 18:20:13.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 18:20:13.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:09:53.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:19:13.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:32.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:33.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-04-14 13:12:55.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-04-14 13:12:55.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:27:49.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:27:49.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:28:59.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:31.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:33.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:34.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:35.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:35.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:35.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:35.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:35.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:35.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:35.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:35.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:35.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:35.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:35.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:35.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-04-14 13:13:29.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:08:27.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:18:28.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-04-05 19:20:29.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 13:54:12.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 13:54:12.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-15 13:54:12.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:35:25.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-01-24 19:52:45.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-31 12:40:52.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-24 19:48:39.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:01:30.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-01-24 19:52:44.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:49:30.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-22 13:09:35.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:49:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-31 12:40:58.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-31 12:40:52.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-15 16:49:05.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:58:03.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-11 19:48:21.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:49:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-24 19:47:35.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:49:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-08-31 12:40:58.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-22 13:09:35.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-24 20:50:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-22 13:09:35.000000","last_name":"Perlov","first_name":"Maor"}],"sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwN25h58KDA","fullname":"Vered Waxman"},"biverifydate":"2019-10-15T00:00:00.000Z","crunchbaseid":"takeda-pharmaceutical","lastupdator":"Maor Perlov","lastupdator_email":"maor.perlov@sncentral.org","creator":"Yanina Wainscheinker","creator_email":"yanina.wain@gmail.com","createdate":"2019-04-05T00:00:00.000Z","lastupdatedate":"2023-01-24","hide_reason":null,"hide_reason_data":null,"logokey":"$2HdbHpFWxsWf3QAG4Lc5sNnioW26PxHDc2IeFTCFgjjPOnaQOl7k6a","name":"Takeda","israeliacquisitions":0,"forbesranking":377,"investmentarm":null,"investmentarmname":null,"hubname":null,"acquired_amount":null,"acquired_by":null,"acquired_country":null,"acquired_month":null,"acquired_year":null,"type":"Multinational","formernames":[],"alternativenames":[""],"country":"Japan","inisraelsince":"11/2013","inisraelsincemonth":"11","isisraeli":0,"marketcapital":42598035776,"marketcapitaldate":"2025-11-01T14:03:11.000Z","oneliner":"Pharmaceuticals","website":"https://www.takeda.com","employees":"51-200","employees_exact":72,"employees_overall":"10,001-50,000","employees_overall_exact":36994,"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/5482","instagram":""},"social":["https://www.linkedin.com/company/5482"],"flattenedsociallinks":"https://www.linkedin.com/company/5482","apps":{"appstore":"","googleplay":""},"investmentstage":[],"about":"Takeda is a global pharmaceutical company based in Japan. The company conducts research and development, manufacturing, and marketing of pharmaceutical products in various therapeutic areas, including oncology, gastroenterology, and central nervous system disorders. Takeda is also involved in the production of vaccines and has a significant presence in the global pharmaceutical market.\n\nTakeda Pharmaceutical Company has a presence in Israel, mainly through its subsidiary Takeda Israel Ltd. The company conducts research and development activities in the country, focusing on areas such as oncology, neuroscience, and rare diseases. Takeda Israel also works with local partners and academic institutions to advance research and development in these areas. Additionally, Takeda Israel is involved in the commercialization and distribution of Takeda's products in Israel.","founded":"1891","team":[{"name":"Tami  Nussbaum ","email":"tami.nussbaum@takeda.com","phone":"","gender":"Female","userid":"f3OQ3PhdHzjE4uaepzPk93SAOR5PIkasJSW3O9TighQOEU5B6O8v9n","bounced":false,"claimed":null,"founder":0,"urlname":"tami-nussbaum","visible":1,"memberid":"CgHeFu1yuKi462E06eiEKuWAbfHxNl3PzmgK0hmmisBiy8RbeLGAMZ","position":"Medical Director","last_name":" Nussbaum ","claimtoken":null,"first_name":"Tami","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/tami-nussbaum-37a52ab0/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"T ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Arie  Kramer","email":"arie.kramer@takeda.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Ljsu44KDA","bounced":false,"claimed":0,"founder":0,"urlname":"arie-kramer","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgmNr62AgM","position":"Country Manager","last_name":"Kramer","claimtoken":"625214e5c81d312ea57bb1773fc01c87b96cb9950b8706b9a8fe1a7c4da8b1ee","first_name":"Arie ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/arie-kramer-6852653/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"AK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Keren Dodick","email":"keren.dodick@takeda.com","phone":"","gender":"female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkPTWsO0LDA","bounced":true,"claimed":null,"founder":0,"urlname":"keren-dodick-1","visible":1,"memberid":"aDWoF9Ed8uMMGgHlNL91NJRqJUUDwp0AaSijjsdU44ujWxOm70RA8T","position":"Director Of External Affairs and Innovation","last_name":"Dodick","claimtoken":null,"first_name":"Keren","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/keren-dodick-682a42112/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"KD","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Michal Zagon-Rogel","email":"michal.zagon-rogel@takeda.com","phone":"","gender":"Female","userid":"8uGBm5NZv6uqweYv0k5Q1L9iHclPP5X9Z6WGf94uMLQ74i4lgsCG27","bounced":false,"claimed":null,"founder":0,"urlname":"michal-zagon-rogel","visible":1,"memberid":"DOMZ9YHGVPWoygyCVMlFYTMczsMh1lMyxhYybW8ouh1GEkgDbz5MkE","position":"External Affairs & communications Manager","last_name":"Zagon-Rogel","claimtoken":"JEAPNTiAM7W2Xd8l1DmgYBq25aExzY7hon4U6levWogV1rWsuEAyao","first_name":"Michal","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/michal-zagon-rogel-19657639/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2023-01-24 19:48:45.000000","initials":"MZ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"portfolio":[{"name":"Protekt Therapeutics ","hidden":false,"raised":"$13.85M","founded":"2014","fullurl":"/company_page/protekt-therapeutics","logokey":"$PUC7R9TDFPF3OWeavgoDg0BM7Cm0A86pfcVq05rYY1jqIa8S27qERK.png","urlname":"protekt-therapeutics","employees":"1-10","company_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwJKrsJMLDA","description":"PKR Inhibition for Treating Neurodegenerative Diseases","fundingstage":"Seed","businessmodel":"B2B","raisedNumber":13850000,"logourl":"https://storage.googleapis.com/clean-finder-353810/$PUC7R9TDFPF3OWeavgoDg0BM7Cm0A86pfcVq05rYY1jqIa8S27qERK.png","style":"","hiddenCompanyTooltip":""}],"exits":[],"mediagallery":[],"affiliatedOrganizations":[{"id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4NWZ7KkIDA","name":"Takeda Ventures","type":"Investor","hidden":false,"fullurl":"/investor_page/takeda-ventures","logokey":"$KF0xFRFBu3GhEyU6Rbs1uLNSoAH4QN1V02b6iNzoHXbS5px8PQ2Q4F","logourl":"https://storage.googleapis.com/clean-finder-353810/$KF0xFRFBu3GhEyU6Rbs1uLNSoAH4QN1V02b6iNzoHXbS5px8PQ2Q4F","onClick":"","visibilityClassName":"","visibilityTooltip":""}],"address":{"israeli":[{"id":"c56e9434-a355-406e-8a76-7d36195d61a8","city":"Petah Tikva","type":["R&D "," Sales "," Innovation Center"],"address":"Ef'al Street 25, Petah Tikva, Israel","placeid":null,"notactive":0,"openeddate":"2013-11-01","registrarid":"514993823","firstrdcenter":0,"registrarname":"Takeda Israel Ltd"}],"officesabroad":[{"id":"CQi8iG9Mtg5wV6o13XHo4NdNRZRDlWABDRxkbsoBDcIwB4oP6FiWbN","city":"Chuo City","address":"2 Chome Nihonbashihoncho, Chuo City, Tokyo 103-0023, Japan","country":"Japan","placeid":null}]},"headquarter_address":"2 Chome Nihonbashihoncho, Chuo City, Tokyo 103-0023, Japan","news":[{"id":"CoKSVm1FanodmTKAoBJYXnEVrZC1I2Gua3u1odXwxm1n2ymYNSxlcC","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/strauss-group-tase-strs-assessing-130928825.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings, valuation","round":null,"company":"Strauss Group","layoffs":null,"summary":"Strauss Group has released its second quarter and half-year earnings, showing a rise in sales for both periods in 2025. Despite the increase in revenue, net income has decreased, indicating potential cost pressures or margin changes. The companys stock has risen by nearly 64% over the past year, though recent gains have slowed. Strauss Groups price-to-earnings ratio is slightly below the Asian Food industry average, suggesting it is valued in line with sector peers. The companys strong profit growth and above-average profit margin support its current valuation. However, potential risks include slowing net income growth or changes in consumer demand.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["earnings","valuation","growth","stock","margins"],"date_of_event":"2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"FOZdAK6ROAG4u2tulcNw5K1hzuE3yeTq79m5eIRi8DnmveFkjSAu0V","news_summary":"Strauss Group (TASE:STRS): Assessing Valuation After Mixed Q2 Earnings and Sales Growth","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"88obO9LBoLtfZIqeyT0IjR5BSjPtQKq9ghbH3oG3DU4Uf4WEwKUthg","date":"Sep 9, 2025","link":"https://www.hotelmanagement-network.com/news/westin-desaru-coast-cayin-technology/","source":"www.hotelmanagement-network.com","visible":1,"analysis":{"tags":"partnership","round":null,"company":"CAYIN Technology","layoffs":null,"summary":"CAYIN Technology has partnered with Westin Desaru Coast Resort in Johor, Malaysia, to enhance guest communication and operational efficiency through the implementation of its CMS-WS server and CAYIN Signage Player. This collaboration involves the use of digital signage to provide real-time updates across 14 Samsung displays in various areas of the resort. The project was executed in partnership with Hola Media, which provided integration services, including installation, design, staff training, and support. The system has improved communication, reduced staff workload, and enhanced the guest experience, preparing the resort for future digital expansion.","partners":"Hola Media","customers":"Westin Desaru Coast Resort","eventType":null,"investors":null,"confidence":9,"key_topics":["partnership","digital signage","hospitality","operational efficiency","guest communication"],"date_of_event":"September 9, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"k5Yj1huWVlFrfm2vyUbW5Xdii8HGJfFMOA5dQmWEoZWmWtAWB7WTfO","news_summary":"Westin Desaru Coast Resort partners with CAYIN Technology for digital signage","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"i593rRbWNDThGlhqRE2CCnkRvIqxLFy33B1Yb4uBaQuz6Dm9y9uZ3D","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/nikkiso-addresses-growing-ammonia-handling-060000400.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"innovation","round":null,"company":"Nikkiso Clean Energy & Industrial Gases Group","layoffs":null,"summary":"Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) announced the launch of a next-generation submerged ammonia pump at the Gastech Conference. This pump is designed to be the safest and most reliable in the industry, addressing common maintenance issues with its seal-less, maintenance-friendly, copper-free construction. The pump can deliver over 2,500m3 per hour and has a mean time between outages of over 16,000 hours. This launch is part of Nikkiso CE&IGs ongoing innovation in ammonia handling, with the company having decades of experience in this field. The pump is expected to meet growing demand for ammonia in various sectors, including power generation and shipping.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["ammonia","pump","innovation","hydrogen","safety"],"date_of_event":"September 09, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2VNok2g511DpuYCdEJvslzcKzPSMNP5dIzmgMLw61kbxPaAtllRFpu","news_summary":"Nikkiso Addresses Growing Ammonia-Handling Demand and Launches Next-Generation Pump at Gastech 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"TFx1Zzacg16Xd0YQBt0ATsmhFFYMe4laPG1hMAsFFRBph6eIxDiuOG","date":"Aug 30, 2022","link":"https://www.marketscreener.com/quote/stock/TAKEDA-PHARMACEUTICAL-COM-6491073/news/Y-mAbs-and-Takeda-Announces-Marketing-Authorization-in-Israel-for-DANYELZA-naxitamab-gqgk-for-Neu-41651127/","source":"www.marketscreener.com","visible":1,"analysis":{"tags":["regulatory approval","commercialization","expanding reach","pediatric patients","unmet medical needs"],"company":"Y-mAbs Therapeutics, Inc.","layoffs":null,"summary":"Y-mAbs Therapeutics, Inc. and Takeda Israel have announced that the Israeli Ministry of Health has approved DANYELZA for the treatment of pediatric patients and adult patients with relapsed or refractory high-risk neuroblastoma. DANYELZA will be commercialized by Takeda Israel under an exclusive license and distribution agreement. This approval marks Y-mAbs first marketing authorization outside of the U.S. and demonstrates their commitment to expanding the reach of their commercial stage products internationally. The approval is seen as a milestone for the collaboration between Y-mAbs and Takeda and is expected to benefit pediatric patients with unmet medical needs. DANYELZA was developed by researchers at Memorial Sloan Kettering Cancer Center and is exclusively licensed by Y-mAbs.","partners":["Takeda Israel"],"customers":null,"investors":null,"confidence":8,"key_topics":["DANYELZA","Takeda Israel","pediatric patients","neuroblastoma","commercialization"],"date_of_event":"2022-08-30","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WyZvCIdxLA8jEoG3rOGSnq2PPgMEpskbJQJ22yQBBAOctEBHU3V35n","news_summary":"Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma | MarketScreener","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"586f8cc5-6599-4207-938a-a9a8adc14b81","date":"Apr 7, 2018","link":"https://www.businesswire.com/news/home/20180407005052/en/Takeda-Israel-Awarded-Place-Work-Israel-2018","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ze18lHhHqM9S82CwpCQaReyaMq8sDzIg1YOs3A7rnXeQIBgLYxigAa","news_summary":"Takeda Israel Awarded the Best Place to Work in Israel for 2018","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"a36c84c6-835a-432a-9142-cc40d4c90e41","date":"May 12, 2015","link":"https://www.jpost.com/Business-and-Innovation/Japan-based-Takeda-readies-strategic-investment-in-Israel-402859","source":"www.jpost.com","visible":1,"analysis":{"tags":"strategic investments","company":"Takeda Pharmaceuticals","layoffs":null,"summary":"Takeda Pharmaceuticals, the largest pharmaceutical company in Asia, is increasing efforts for strategic investments in Israel through its venture fund. The company is looking to fund promising seed companies that fit in with its strategic vision. Takeda launched a commercial subsidiary in Israel in 2013 and helped establish a biotech accelerator called FutuRx in 2014. Takeda is now doing diligence on several promising prospects for investment. The expansion in Israel is part of the companys strategy to engage more globally and tap into innovation outside of its traditional markets. Takeda sees the future in greater personalization of medicine and is attending the IATI Biomed conference in Israel to explore opportunities.","partners":["OrbiMed Israel Partners","Johnson & Johnson Innovation"],"customers":null,"investors":null,"confidence":8,"key_topics":["Takeda Pharmaceuticals","strategic investments","Israel","venture fund","biotech"],"date_of_event":"2015-05-12","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"hGHocRbw0O91KdcBT9bAan67LHxAfR7uHx6kqdtKMBCtz6IRsFNE7C","news_summary":"https://www.jpost.com/Business-and-Innovation/Japan-based-Takeda-readies-strategic-investment-in-Israel-402859","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"extensions":[{"id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4NWZ7KkIDA","name":"Takeda Ventures","type":"Investor","hidden":false,"logokey":"$KF0xFRFBu3GhEyU6Rbs1uLNSoAH4QN1V02b6iNzoHXbS5px8PQ2Q4F","subtype":"Corporate VC","urlname":"takeda-ventures","isisraeli":0,"entitytype":"Investor","fullUrlname":"/investor_page/takeda-ventures","fundingstages":["Seed","A Round","B Round"]}],"events":null,"hide_reasons":[{"id":"75T5aG1f0dpqYFonup40lXNjO046zUH82TaHW1TAiIMf9aYAsSOl0d","reason":"No relevant activity"},{"id":"7KVi9S7qqUtO0WCsFclwqBEZluejfNYqWC1Uhx0tPHtDxtvxPPaCPH","reason":"No longer active"},{"id":"hoyKAmu4YJEHmhtLwCdeFldSnDwaVbPXOnH0RA9hKHCzAcHO6OOrXd","reason":"Pending approval"},{"id":"TC54H7CXyKO8GmPECkbyKJf8n34r70JlfJTJHfo85exRpLaKI1Efs9","reason":"Pending approval - External entity"}],"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODo1vbRCgw","hub":null,"date":"2018-12-01","batch":"","token":"","amount":null,"hub_id":null,"source":"https://www.thepharmaletter.com/in-brief/brief-takeda-announces-nyse-listing","ticker":"TAK","enddate":"","mnatype":null,"eventtype":"POEvent","granttype":null,"valuation":null,"investment":[],"hub_logokey":null,"hub_urlname":null,"wasacquired":null,"delistreason":null,"capitalraised":null,"stockexchange":"NYSE","eventvisibility":"Public","amountvisibility":null,"duetoacquisition":null,"isextensionround":null,"token_visibility":"","fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIgdygCww","acquiredcompany_mna":null,"communitycompany_id":null,"isjointventuregrant":null,"acquiredcompany_spac":"Undisclosed","communitycompany_name":null,"communitycompany_type":null,"stockexchange_logokey":"$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","acquiredcompany_mna_id":null,"fundingtypefundingtype":null,"acquiredcompany_reverse":null,"acquiredcompany_spac_id":null,"communitycompany_hidden":null,"communitycompany_fullurl":null,"communitycompany_logokey":null,"communitycompany_urlname":null,"acquiredcompany_reverse_id":null,"acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":null,"acquiredcompany_mna_homepage":null,"acquiredcompany_spac_logokey":null,"acquiredcompany_spac_homepage":null,"acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":null,"acquiredcompany_reverse_homepage":null,"hub_logourl":"/assets/empty-state.svg","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","communitycompany_logourl":"/assets/empty-state.svg","acquiredcompany_mna_logourl":"/assets/empty-state.svg","acquiredcompany_spac_logourl":"/assets/empty-state.svg","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","style":"","hiddenCompanyTooltip":""},{"id":"nNvFQqFSqCLFwWYBgOVtgDu8HANFg8WFnmnFP2wozpsxt4t0iPxRcj","hub":null,"date":"2013-12-01","batch":"","token":"","amount":null,"hub_id":null,"source":"","ticker":"4502","enddate":"","mnatype":null,"eventtype":"POEvent","granttype":null,"valuation":null,"investment":[],"hub_logokey":null,"hub_urlname":null,"wasacquired":null,"delistreason":null,"capitalraised":null,"stockexchange":"TYO","eventvisibility":"Public","amountvisibility":null,"duetoacquisition":null,"isextensionround":null,"token_visibility":"","fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJCAzufpCQw","acquiredcompany_mna":null,"communitycompany_id":null,"isjointventuregrant":null,"acquiredcompany_spac":"Undisclosed","communitycompany_name":null,"communitycompany_type":null,"stockexchange_logokey":"$AXpg88mIlK6h2vmilApaRvq7e8myJ5mgetrfFsfXJt6TIzljQPrWyt","acquiredcompany_mna_id":null,"fundingtypefundingtype":null,"acquiredcompany_reverse":null,"acquiredcompany_spac_id":null,"communitycompany_hidden":null,"communitycompany_fullurl":null,"communitycompany_logokey":null,"communitycompany_urlname":null,"acquiredcompany_reverse_id":null,"acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":null,"acquiredcompany_mna_homepage":null,"acquiredcompany_spac_logokey":null,"acquiredcompany_spac_homepage":null,"acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":null,"acquiredcompany_reverse_homepage":null,"hub_logourl":"/assets/empty-state.svg","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AXpg88mIlK6h2vmilApaRvq7e8myJ5mgetrfFsfXJt6TIzljQPrWyt","communitycompany_logourl":"/assets/empty-state.svg","acquiredcompany_mna_logourl":"/assets/empty-state.svg","acquiredcompany_spac_logourl":"/assets/empty-state.svg","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","style":"","hiddenCompanyTooltip":""}],"techcommunityinvolvement":null,"tags":["neuroscience","pharmaceuticals","gastroenterology","oncology","rare-diseases","innovation-center"],"investments":[],"funds":[],"databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"10,001-50,000","fundingtype":"Multinational","parsedName":"Takeda","logourl":"https://storage.googleapis.com/clean-finder-353810/$2HdbHpFWxsWf3QAG4Lc5sNnioW26PxHDc2IeFTCFgjjPOnaQOl7k6a","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$2HdbHpFWxsWf3QAG4Lc5sNnioW26PxHDc2IeFTCFgjjPOnaQOl7k6a","teamMembersNumber":4,"nationality":"Foreign","communityinvolvement":[],"popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none"},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}